266 related articles for article (PubMed ID: 16733150)
1. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study.
Cerfolio RJ; Bryant AS; Ojha B
J Thorac Cardiovasc Surg; 2006 Jun; 131(6):1229-35. PubMed ID: 16733150
[TBL] [Abstract][Full Text] [Related]
2. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
[TBL] [Abstract][Full Text] [Related]
3. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy.
Cerfolio RJ; Bryant AS; Ohja B; Bartolucci AA; Eloubeidi MA
J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1232-41. PubMed ID: 15942562
[TBL] [Abstract][Full Text] [Related]
4. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer.
Cerfolio RJ; Ojha B; Bryant AS; Raghuveer V; Mountz JM; Bartolucci AA
Ann Thorac Surg; 2004 Sep; 78(3):1017-23; discussion 1017-23. PubMed ID: 15337041
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer.
Lee PC; Port JL; Korst RJ; Liss Y; Meherally DN; Altorki NK
Ann Thorac Surg; 2007 Jul; 84(1):177-81. PubMed ID: 17588407
[TBL] [Abstract][Full Text] [Related]
6. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives.
Cerfolio RJ; Maniscalco L; Bryant AS
Ann Thorac Surg; 2008 Sep; 86(3):912-20; discussion 912-20. PubMed ID: 18721582
[TBL] [Abstract][Full Text] [Related]
7. Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer.
Cerfolio RJ; Bryant AS
Ann Thorac Surg; 2008 Aug; 86(2):362-6; discussion 366-7. PubMed ID: 18640297
[TBL] [Abstract][Full Text] [Related]
8. Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer.
Yang W; Fu Z; Yu J; Yuan S; Zhang B; Li D; Xing L; Zhao D; Mu D; Sun X; Fang Y; Huang Y; Li W
Lung Cancer; 2008 Jul; 61(1):35-43. PubMed ID: 18177978
[TBL] [Abstract][Full Text] [Related]
9. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a closer look at redo mediastinoscopy.
Granone P; Van Schil P; Cesario A
J Thorac Cardiovasc Surg; 2007 Jan; 133(1):275-6; author reply 276-7. PubMed ID: 17198837
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer.
Meyers BF; Haddad F; Siegel BA; Zoole JB; Battafarano RJ; Veeramachaneni N; Cooper JD; Patterson GA
J Thorac Cardiovasc Surg; 2006 Apr; 131(4):822-9; discussion 822-9. PubMed ID: 16580440
[TBL] [Abstract][Full Text] [Related]
11. Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial.
D'Cunha J; Herndon JE; Herzan DL; Patterson GA; Kohman LJ; Harpole DH; Kernstine KH; Kern JA; Green MR; Maddaus MA; Kratzke RA;
Lung Cancer; 2005 May; 48(2):241-6. PubMed ID: 15829324
[TBL] [Abstract][Full Text] [Related]
12. Remediastinoscopy in restaging of lung cancer after induction therapy.
Marra A; Hillejan L; Fechner S; Stamatis G
J Thorac Cardiovasc Surg; 2008 Apr; 135(4):843-9. PubMed ID: 18374765
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of advantages of positron emission tomography over computed tomography for N-staging in lung cancer patients.
Ebihara A; Nomori H; Watanabe K; Ohtsuka T; Naruke T; Uno K; Kuwahira I; Eguchi K
Jpn J Clin Oncol; 2006 Nov; 36(11):694-8. PubMed ID: 17068084
[TBL] [Abstract][Full Text] [Related]
14. Predictors of survival and disease-free survival in patients with resected N1 non-small cell lung cancer.
Cerfolio RJ; Bryant AS
Ann Thorac Surg; 2007 Jul; 84(1):182-8; discussion 189-90. PubMed ID: 17588408
[TBL] [Abstract][Full Text] [Related]
15. Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy.
Tan A; Adelstein DJ; Rybicki LA; Saxton JP; Esclamado RM; Wood BG; Lorenz RR; Strome M; Carroll MA
Arch Otolaryngol Head Neck Surg; 2007 May; 133(5):435-40. PubMed ID: 17515501
[TBL] [Abstract][Full Text] [Related]
16. Survival of patients with true pathologic stage I non-small cell lung cancer.
Cerfolio RJ; Bryant AS
Ann Thorac Surg; 2009 Sep; 88(3):917-22; discussion 922-3. PubMed ID: 19699920
[TBL] [Abstract][Full Text] [Related]
17. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients.
Ohno Y; Koyama H; Nogami M; Takenaka D; Yoshikawa T; Yoshimura M; Ohbayashi C; Sugimura K
J Magn Reson Imaging; 2007 Oct; 26(4):1071-80. PubMed ID: 17896365
[TBL] [Abstract][Full Text] [Related]
18. Repeat mediastinoscopy in all its indications: experience with 96 patients and 101 procedures.
Call S; Rami-Porta R; Obiols C; Serra-Mitjans M; Gonzalez-Pont G; Bastús-Piulats R; Quintana S; Belda-Sanchis J
Eur J Cardiothorac Surg; 2011 Jun; 39(6):1022-7. PubMed ID: 21112217
[TBL] [Abstract][Full Text] [Related]
19. [Multimodal treatment of non small cell lung cancer].
Stoelben E; Digel W; Henke M; Passlick B
Zentralbl Chir; 2006 Apr; 131(2):110-4. PubMed ID: 16612776
[TBL] [Abstract][Full Text] [Related]
20. Baseline SUVmax at PET-CT in stage IIIA non-small-cell lung cancer patients undergoing surgery after neoadjuvant therapy: prognostic implication focused on histopathologic subtypes.
Lee HY; Lee KS; Park J; Han J; Kim BT; Kwon OJ; Ahn YC; Ahn MJ; Park K; Kim J; Shim YM
Acad Radiol; 2012 Apr; 19(4):440-5. PubMed ID: 22265854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
